A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies

Radiotherapy and Oncology

Volumn 88, Issue 1, 2008, Pages 53-60

  Supiot, Stephane ^a,b   Shubbar, Shubber ^a,b   Fleshner, Neil ^a,c   Warde, Padraig ^a,b   Hersey, Karen ^a   Wallace, Kris ^a   Cole, Heather ^a   Sweet, Joan ^a,c   Tsihlias, John ^d   Jewett, Michael A S ^a,c   Klotz, Laurence ^c   Bristow, Robert G ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d William Osler Health Centre   (Canada)

Author keywords

Apoptosis; Cell cycle arrest; p21WAF; p53; Pre operative radiotherapy; Radical prostatectomy; Senescence

Indexed keywords

ATM PROTEIN; CORTICOSTEROID; CYCLIN DEPENDENT KINASE INHIBITOR; PHENAZOPYRIDINE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DISEASE SEVERITY; DNA DAMAGE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; MORBIDITY; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATITIS; RADIATION DOSE; RECTUM HEMORRHAGE; TREATMENT OUTCOME; TUMOR GROWTH; URINE INCONTINENCE;

ADENOCARCINOMA; AGED; APOPTOSIS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 45849091146     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.03.019     Document Type: Article

References (38)

1. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
2. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
3. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol 2005. ASCO Annual Meeting Proceedings 2005;23(6S, Part I of II (June 1 Supplement)):4513.
4. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
5. Jereczek-Fossa B.A., and Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 84 (2007) 197-215
6. Fonteyne V., De Neve W., Villeirs G., De Wagter C., and De Meerleer G. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 84 (2007) 156-163
7. De Meerleer G.O., Fonteyne V.H., Vakaet L., et al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 82 (2007) 160-166
8. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980-7.
9. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001) 638-646
10. Bromfield G.P., Meng A., Warde P., and Bristow R.G. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 6 (2003) 73-85
11. Nichol A.M., Warde P., and Bristow R.G. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 104 (2005) 891-905
12. Bristow R.G., Ozcelik H., Jalali F., Chan N., and Vesprini D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother Oncol 83 (2007) 220-230
13. Nichol A., Chung P., Lockwood G., et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 76 (2005) 11-17
14. Skala M., Rosewall T., Dawson L., et al. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2007)
15. Wu J., Haycocks T., Alasti H., et al. Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 61 (2001) 127-133
16. Bayley A.J., Catton C.N., Haycocks T., et al. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiother Oncol 70 (2004) 37-44
17. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973-3978
18. Meng A.X., Jalali F., Cuddihy A., et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 76 (2005) 168-176
19. Stephenson A.J., Scardino P.T., Bianco Jr. F.J., DiBlasio C.J., Fearn P.A., and Eastham J.A. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 172 (2004) 2239-2243
20. Stephenson A.J., and Eastham J.A. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 23 (2005) 8198-8203
21. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751-756
22. Loeb S., Smith N.D., Roehl K.A., and Catalona W.J. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69 (2007) 1170-1175
23. Wei J.T., Dunn R.L., Marcovich R., Montie J.E., and Sanda M.G. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 164 (2000) 744-748
24. Sacco E., Prayer-Galetti T., Pinto F., et al. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 97 (2006) 1234-1241
25. Gheiler E.L., Tefilli M.V., Tiguert R., et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51 (1998) 789-795
26. Amling C.L., Lerner S.E., Martin S.K., Slezak J.M., Blute M.L., and Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 161 (1999) 857-862 [discussion 62-3]
27. Ward J.F., Sebo T.J., Blute M.L., and Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173 (2005) 1156-1160
28. Peeters K.C., van de Velde C.J., Leer J.W., et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - a Dutch colorectal cancer group study. J Clin Oncol 23 (2005) 6199-6206
29. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., Myers R.P., and Blute M.L. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 172 (2004) 1328-1332
30. Bott S.R., Freeman A.A., Stenning S., Cohen J., and Parkinson M.C. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int 95 (2005) 34-39
31. Marijnen C.A., Nagtegaal I.D., Klein-Kranenbarg E., et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 19 (2001) 1976-1984
32. Klotz L.H., Goldenberg S.L., Jewett M., et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 53 (1999) 757-763
33. Fowler J.F., Ritter M.A., Chappell R.J., and Brenner D.J. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 56 (2003) 1093-1104
34. Martin J.M., Rosewall T., Bayley A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys. (2007)
35. Schmitt C.A. Cellular senescence and cancer treatment. Biochim Biophys Acta 1775 (2007) 5-20
36. Shay J.W., and Roninson I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23 (2004) 2919-2933
37. Van der Kwast T.H., Collette L., and Bolla M. Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. J Clin Oncol 25 (2007) 5671-5672
38. Peeters K.C., Marijnen C.A., Nagtegaal I.D., et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246 (2007) 693-701